These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23646396)

  • 1. [Drug now immediately available in Germany].
    Aktuelle Urol; 2006 Sep; 37(5 Suppl):18-9. PubMed ID: 23646396
    [No Abstract]   [Full Text] [Related]  

  • 2. Spontaneous regression of metastatic papillary renal cell cancer after cessation of treatment with sorafenib.
    Grenader T; Rosenbaum E; Zilber S; Bogot N; Shavit L
    Clin Genitourin Cancer; 2013 Jun; 11(2):201-3. PubMed ID: 23266054
    [No Abstract]   [Full Text] [Related]  

  • 3. Relationship of pathologic factors to efficacy of sorafenib treatment in patients with metastatic clear cell renal cell carcinoma.
    Araki H; Tsuzuki T; Kimura T; Tanaka K; Yamada S; Sassa N; Yoshino Y; Hattori R; Gotoh M
    Am J Clin Pathol; 2015 Apr; 143(4):492-9. PubMed ID: 25780000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pneumatosis intestinalis and hepatic portal venous gas in a patient receiving sorafenib.
    Kashima T; Ohno Y; Tachibana M
    Int J Urol; 2012 Nov; 19(11):1041-2. PubMed ID: 22788573
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of First-Line Sorafenib Treatment for Metastatic Renal Cell Carcinoma in Kidney Transplant Patients: A Single-Center Experience With Four Cases.
    Ishihara H; Kondo T; Tanabe K
    Ther Apher Dial; 2017 Aug; 21(4):414-416. PubMed ID: 28593648
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group.
    Tafreshi A; Thientosapol E; Liew MS; Guo Y; Quaggiotto M; Boyer M; Davis ID
    Asia Pac J Clin Oncol; 2014 Mar; 10(1):60-5. PubMed ID: 24152417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of pathological features of primary lesion in metastatic renal cell carcinoma treated with sorafenib.
    Gu W; Wang B; Gan H; Zhu Y; Wang H; Shi G; Zhou L; Zhang H; Ye D
    Future Oncol; 2016 Aug; 12(15):1783-93. PubMed ID: 27174049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of antiangiogenic therapy.
    von Falck C; Wacker F; Rosenthal H
    J Vasc Interv Radiol; 2012 Nov; 23(11):1503. PubMed ID: 23101922
    [No Abstract]   [Full Text] [Related]  

  • 9. A Case of Pancreatic Side Effects Resulting from Sorafenib and Axitinib Treatment of Stage IV Renal Cell Carcinoma.
    Kitamura Y; Yoshii H; Nishimoto K; Shinchi Y; Tokonabe S; Takao M; Daido Y
    Keio J Med; 2015; 64(4):62-4. PubMed ID: 26727578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical activity of sorafenib in a previously treated advanced urothelial cancer patient.
    Shah CH; Viktorsson K; Sherif A; Kanter L; Grybäck P; Lewensohn R; Sandström P; Nilsson S; Ullén A
    Anticancer Drugs; 2013 Jul; 24(6):648-52. PubMed ID: 23542751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Slow and steady wins the race: practical (and philosophical) considerations of treatment activity evaluation when novel anticancer agents just slow neoplastic progression.
    Porta C; Vercelli A; Paglino C
    Eur Urol; 2014 Apr; 65(4):721-2. PubMed ID: 24007714
    [No Abstract]   [Full Text] [Related]  

  • 12. Axitinib in advanced renal-cell carcinoma.
    Yousaf N; Larkin J
    Lancet Oncol; 2013 Dec; 14(13):1245-6. PubMed ID: 24206641
    [No Abstract]   [Full Text] [Related]  

  • 13. Sorafenib in renal cell carcinoma.
    Davoudi ET; bin-Noordin MI; Javar HA; Kadivar A; Sabeti B
    Pak J Pharm Sci; 2014 Jan; 27(1):203-8. PubMed ID: 24374450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preserving the sanctity of overall survival for drugs approved on the basis of progression-free survival: tivozanib as a case study.
    Garnick MB
    J Clin Oncol; 2013 Oct; 31(30):3746-8. PubMed ID: 24019543
    [No Abstract]   [Full Text] [Related]  

  • 15. Results of the first trial assessing adjuvant tyrosine kinase inhibitors in renal cell carcinoma do not reASSURE.
    Ouzaid I; Bensalah K
    Eur Urol; 2015 Sep; 68(3):542-3. PubMed ID: 26001611
    [No Abstract]   [Full Text] [Related]  

  • 16. Pituitary metastasis from a renal cell carcinoma progressed after sorafenib treatment.
    Yang L; Yu SY; Hu GY
    Chin J Cancer; 2013 Jun; 32(6):353-6. PubMed ID: 23237217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [ASCO 2006: temsirolimus increases survival].
    Aktuelle Urol; 2006 Sep; 37(5 Suppl):12. PubMed ID: 23646393
    [No Abstract]   [Full Text] [Related]  

  • 18. Third-line dovitinib in metastatic renal cell carcinoma.
    Schmidinger M
    Lancet Oncol; 2014 Mar; 15(3):245-6. PubMed ID: 24556039
    [No Abstract]   [Full Text] [Related]  

  • 19. c-KIT: potential predictive factor for the efficacy of sorafenib in metastatic renal cell carcinoma with sarcomatoid feature.
    Zhang HL; Zhu Y; Qin XJ; Wang CF; Yao XD; Zhang SL; Dai B; Zhu YP; Shi GH; Ye DW
    Clin Genitourin Cancer; 2013 Jun; 11(2):134-40. PubMed ID: 23058498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: Börje Ljungberg, Damian C. Hanbury, Marcus A. Kuczyk, Axel S. Merseburger, Peter F.A. Mulders, Jean-Jaques Patard and Ioanel C. Sinescu. Renal cell cacinoma guideline. Eur Urol 2007;51:1502-10.
    Di Lorenzo G
    Eur Urol; 2007 Sep; 52(3):926-8; author reply 928. PubMed ID: 17574728
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.